Merz Pharmaceuticals' Belotero(R) Balance PMA Filing Formally Accepted for Review by the FDA
Posted on: Friday, 11 September 2009, 08:55 CDT
GREENSBORO, N.C., Sept. 11 /PRNewswire/ -- Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz's premarket approval (PMA) application for Belotero(R) Balance.
Belotero(R) Balance is a hyaluronic acid based monophasic gel dermal filler that utilizes a cohesive polydensified matrix (CPM(TM)) technology. This application seeks FDA approval for injection into mid-to-deep dermis for correction of moderate to severe wrinkles and folds.
"The FDA's acceptance for review of the Belotero(R) Balance PMA begins the application review process and signifies the beginning of Merz Pharmaceutical's firm footprint in the American aesthetics market," said Jack Britts, president and CEO of Merz Pharmaceuticals, LLC.
"Upon approval, Belotero(R) Balance will be an exciting addition to the dermal filler category," said Dr. Rhoda S. Narins, M.D., the lead investigator for the Belotero(R) clinical trials.
About Belotero(R)
First launched in Germany in 2005, Belotero(R) is also approved for aesthetic use in the United Kingdom, Italy, Russia, Austria and Switzerland.
About Merz Pharmaceuticals
Merz Pharmaceuticals, LLC, a wholly owned, U.S. subsidiary of the Merz Group of Companies was established in 1995 and develops and commercializes prescription products for Neurology, Dermatology, Podiatry and the #1 non-prescription product for scars, Mederma.
With a 101 year heritage, Merz (KGaA) is known worldwide for its development of original compounds and formulations for medical professionals and consumers in 90 countries. Globally, Merz is a leader in the development of pharmaceuticals for the treatment of neurological and psychological disorders as well as for aesthetic medicine, including products for the treatment of wrinkles and aging skin, hair loss and acne. Research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.
SOURCE Merz Pharmaceuticals, LLC
Source: PR Newswire
Related Articles
- Ovation Pharmaceuticals's ATryn BLA Accepted for Review By FDA
- Pipex Pharmaceuticals Completes Type A Meeting With FDA for Oral Tetrathiomolybdate New Drug Application
- King Pharmaceuticals Files Citizen Petition With FDA Asserting ZymoGenetics Has Not Submitted Adequate Data for Approval of Its Recombinant Thrombin Product
- Encysive Pharmaceuticals Receives Written Response From FDA On Its Request for Formal Dispute Resolution for THELIN (Sitaxsentan Sodium)
- Solvay Pharmaceuticals, Inc. And Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
- Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Provigil(R)
- Adolor's Complete Response to Approvable Letter for Entereg(R) (Alvimopan) in POI Accepted for Review By FDA; FDA Performance Goal Date is Targeted for November 2006
- Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval For Generic Coreg(R) Tablets
- Par Pharmaceutical's Partner Receives Final Approval to Market Ribavirin Tablets
- Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Zolpidem Tartrate
 |
 |
User Comments (0)
RSS Feeds